JUL 29, 2020 10:30 AM PDT

Will We Have a COVID-19 Vaccine by Year-End?

WRITTEN BY: Annie Lennon

This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 vaccines. Both say that their vaccines may be available for general use by the end of the year. 

The vaccines are based upon a relatively new practice in which synthetic molecules that mimic the coronavirus are injected into patients instead of the virus itself. In doing so, they teach the immune system to fend off the real thing, while being safe from potential side effects of having it introduced to the body. 

Although faster than traditional production methods and thus easily scalable, as the practice is relatively new, it does not have an extensive track record for efficacy. 

Nevertheless, announcements for the trials come as a part of the US government-funded COVID-19 Prevention Network that plans to roll out studies of leading vaccine candidates every month- each with 30,000 newly recruited volunteers. Aside from seeing if the vaccines work, researchers hope to verify each vaccine's safety profile and then compare results. 

All of this means that large numbers of people will be required to partake in trials, which can often be problematic. Dr. Larry Corey, a virologist who helps oversee the study sites, has said, however, that over 150,000 Americans have already signaled interest in the treatment in online registries. 

While Moderna has received almost $1 billion from the US government to help roll out its vaccine, Pfizer has agreed to sell enough vaccines for 50 million people in the US for around $2 billion should their vaccine work. 

Pfizer has also said that it aims to have around 1.3 billion doses available by the end of 2021- enough to treat 650 million people at two doses each. Meanwhile, Moderna aims to manufacture between 500 million and 1 billion doses per year.

 

Sources: CNBCWashington PostReuters

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 24, 2020
Drug Discovery & Development
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
AUG 24, 2020
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help th ...
AUG 29, 2020
Drug Discovery & Development
MDMA and LSD Combo to Enter Clinical Trials
AUG 29, 2020
MDMA and LSD Combo to Enter Clinical Trials
Scientists from the pharmaceutical company, MindMed, have announced the beginning of Phase 1 clinical trials to test Sch ...
SEP 08, 2020
Drug Discovery & Development
Common Steroid Drug Reduces COVID-19 Deaths by 20%
SEP 08, 2020
Common Steroid Drug Reduces COVID-19 Deaths by 20%
Hydrocortisone, a common and widely-available anti-inflammatory steroid drug, has been found to reduce the mortality rat ...
OCT 15, 2020
Neuroscience
Neurometabolism: A bold, new frontier
OCT 15, 2020
Neurometabolism: A bold, new frontier
Billions of neurons communicate with each other through trillions of synapses to create a functioning, unique system we ...
OCT 15, 2020
Cannabis Sciences
Can Cannabis Treat Traumatic Brain Injury?
OCT 15, 2020
Can Cannabis Treat Traumatic Brain Injury?
Traumatic brain injury (TBI) happens when the head is violently hit by an object or when an object pierces the skull and ...
OCT 20, 2020
Drug Discovery & Development
New Treatment Reverses Late Stage Type 2 Diabetes
OCT 20, 2020
New Treatment Reverses Late Stage Type 2 Diabetes
Researchers from the Netherlands have developed a minimally invasive therapeutic procedure that allows people to discont ...
Loading Comments...